Sweet's syndrome associated with Crohn's disease

Lima, Caren dos Santos; Pinto, Roberta Duarte Bezerra; Góes, Heliana Freitas de Oliveira; Salles, Simone de Abreu Neves; Vilar, Enoí Aparecida Guedes; Lima, Carla dos Santos

doi:10.1590/abd1806-4841.20175298

Cited by 6 publications

(12 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After the introduction of CS, cutaneous manifestations reliably disappeared in every pregnancy except in the last one. As the spontaneous healing of lesions may take weeks to months, topical or systemic treatment is recommended, especially in highly symptomatic cases [7]. Relapsing and resistant forms can be treated with immunomodulators or anti-TNF agents.…”

Section: Discussionmentioning

confidence: 99%

Pregnancy-Induced Sweet’s Syndrome Treated with Infliximab

et al. 2018

View full text Add to dashboard Cite

Objective: To present a case of relapsing and resistant Sweet’s syndrome that developed during pregnancy together with an onset of Crohn’s disease, showing complete resolution with the use of infliximab. Clinical Presentation and Intervention: A 30-year-old pregnant woman presented with fever, skin lesions, and diarrhea. Skin biopsy confirmed neutrophilic dermatosis and she was diagnosed with Crohn’s disease after endoscopy. There was no recurrence of Sweet’s syndrome outside of her pregnancy. During a previous pregnancy, while corticosteroids were ineffective, complete regression of skin lesions was achieved using infliximab. Conclusion: The “off-label” use of infliximab is beneficial for relapsing and resistant Sweet’s syndrome.

show abstract

Section: Discussionmentioning

confidence: 99%

Pregnancy-Induced Sweet’s Syndrome Treated with Infliximab

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The relationship of Sweet's syndrome with IBD has been repeatedly documented in the literature in the form of numerous case reports. Inflammatory bowel disease is considered to be the third most common group of diseases associated with Sweet's syndrome, although it is very difficult to establish the frequency of coexistence of both diseases due to the rare occurrence of this dermatosis [8,19].…”

Section: Sweet's Syndromementioning

confidence: 99%

“…A special form of Sweet's syndrome is the bullous form, in which blisters, filled with blood or serous content, dominate. After their rupture, superficial ulcerations may form [18][19][20]. As in pyoderma gangrenosum, neutrophilic infiltrates are sometimes present in in-dziejącą, indukowaną lekami, krostkową, pęcherzową, bujającą i pooperacyjną.…”

Section: Sweet's Syndromementioning

confidence: 99%

“…Związek zespołu Sweeta z NZJ został wielokrotnie potwierdzony w piśmiennictwie w postaci licznych opisów przypadków. Nieswoiste zapalenia jelit uważane są za trzecią najczęstszą grupę chorób związanych z zespołem Sweeta, jednak ustalenie częstości współistnienia obu jednostek jest bardzo trudne ze względu na rzadkość występowania tej dermatozy [8,19].…”

Section: Zespół Sweetaunclassified

“…In laboratory tests, neutrophilia and elevated inflammatory markers are characteristic. The mainstay of treatment is local and systemic steroid therapy, usually resulting in rapid improvement [18,19].…”

Section: Zespół Sweetamentioning

confidence: 99%

See 2 more Smart Citations

Dermatological changes associated with non-specific inflammatory bowel diseases – Crohn’s disease and ulcerative colitis

Hołdrowicz¹,

Woźniacka²

2020

View full text Add to dashboard Cite

Systematic Review: Sweet Syndrome Associated with Inflammatory Bowel Disease

Sleiman

Hitawala

Cohen

et al. 2021

Journal of Crohn's and Colitis

View full text Add to dashboard Cite

Background and Aims Sweet syndrome [SS] is a dermatological condition associated with both inflammatory bowel disease [IBD] and azathioprine use. We performed a systematic review to better delineate clinical characteristics and outcomes of SS in IBD patients. Methods Peer-reviewed, full-text journal publications from inception to April 2020 in English language and adult subjects with IBD were included. Skin biopsy was required as SS gold-standard diagnosis. Azathioprine-associated SS required recent azathioprine introduction or recurrence of SS after azathioprine re-challenge. Results We included 89 publications with 95 patients [mean age of SS diagnosis: 44 years; 59% female; 20 with azathioprine-associated SS and 75 without]. SS was diagnosed prior to IBD in 5.3%, at time of IBD diagnosis in 29.5% and after diagnosis in 64.2%. In total, 91% of patients with SS had known colonic involvement and the majority [76%] had active IBD at diagnosis; 22% had additional extra-intestinal manifestations. Successful therapies for SS included corticosteroids [90.5%], anti-tumour necrosis factor [TNF]-α inhibitor therapy [14.8%] and azathioprine [11.6%]. Azathioprine-associated SS was distinct, with 85% male patients, mean age of SS diagnosis of 50 years and a lower likelihood to be prescribed corticosteroids for treatment [75% vs 94.7% of non-azathioprine-associated SS, p = 0.008]. All patients with azathioprine-associated SS improved with medication cessation and developed recurrence after re-challenge. Conclusions SS may precede or occur with IBD diagnosis in almost one-third of cases. Azathioprine and IBD-associated SS present and behave distinctly, especially with regard to gender, age at diagnosis and recurrence risk. Corticosteroids and TNF-α inhibitors have demonstrated efficacy in treating SS in IBD.

show abstract

Sweet's syndrome associated with Crohn's disease

Cited by 6 publications

References 9 publications

Pregnancy-Induced Sweet’s Syndrome Treated with Infliximab

Pregnancy-Induced Sweet’s Syndrome Treated with Infliximab

Dermatological changes associated with non-specific inflammatory bowel diseases – Crohn’s disease and ulcerative colitis

Systematic Review: Sweet Syndrome Associated with Inflammatory Bowel Disease

Contact Info

Product

Resources

About